Want to see MTVA full AI Analyst Report?
MTVA Stock Chart & Stats
$1.48
-$0.06(-4.05%)
At close: 4:00 PM EDT
$1.48
-$0.06(-4.05%)
Day’s Range― - ―
52-Week Range$0.97 - $19.02
Previous CloseN/A
Volume63.12K
Average Volume (3M)3.42M
Market Cap
$9.82M
Enterprise Value-$3.97
Total Cash (Recent Filing)$12.63M
Total Debt (Recent Filing)$177.00K
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Nov 16, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.07
Shares Outstanding6,588,101
10 Day Avg. Volume118,677
30 Day Avg. Volume3,419,960
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.95
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$14.00Price Target Upside845.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy & TolerabilityRobust Phase 1 weight-loss results with favorable tolerability and completion of dose titration signal durable clinical potential. Consistent efficacy and safety at target doses strengthen prospects for pivotal development, regulatory interactions, and partner interest across obesity and liver-disease indications.
Pipeline Breadth & Combination StrategyHaving two differentiated assets (DA-1726 and vanoglipel) and demonstrated combo synergy materially reduces binary program risk. A versatile backbone therapy strategy broadens addressable markets (MASH, T2D, obesity), improving long-term partnering and commercialization optionality if clinical results continue to validate combinations.
Low Leverage And Equity CushionMinimal debt and a still-positive equity base reduce fixed financial obligations and interest sensitivity, giving management flexibility in structuring financings and partnerships. This conservatism in leverage supports operational resilience while the company advances clinical programs over the medium term.
Bears Say
Pre-revenue Cash BurnSubstantial negative operating and free cash flow reflect ongoing funding of clinical development with no operating inflows. Persistent cash burn forces repeated external financing rounds, constrains strategic optionality, and elevates execution risk if capital markets tighten or trial timelines slip.
Reliance On Equity FinancingUse of ATM offerings and recent equity-plan approvals indicate structural dependence on equity issuance to fund operations. This increases dilution risk for shareholders, may complicate long-term incentive alignment, and signals limited near-term non-dilutive financing alternatives for advancing late-stage programs.
Eroding Equity & Sustained LossesDeclining shareholders' equity and persistent negative returns on equity reflect that cumulative losses are eroding the balance sheet. Without revenue generation, continued losses reduce financial flexibility, heighten refinancing needs, and raise long-term solvency and dilution concerns if clinical milestones are delayed.
MetaVia News
MTVA FAQ
What was MetaVia’s price range in the past 12 months?
MetaVia lowest stock price was $0.97 and its highest was $19.02 in the past 12 months.
What is MetaVia’s market cap?
MetaVia’s market cap is $9.82M.
When is MetaVia’s upcoming earnings report date?
MetaVia’s upcoming earnings report date is Nov 16, 2026 which is in 91 days.
How were MetaVia’s earnings last quarter?
MetaVia released its earnings results on Aug 06, 2026. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.82 by -$0.08.
Is MetaVia overvalued?
According to Wall Street analysts MetaVia’s price is currently Undervalued.
Does MetaVia pay dividends?
MetaVia does not currently pay dividends.
What is MetaVia’s EPS estimate?
MetaVia’s EPS estimate is -0.74.
How many shares outstanding does MetaVia have?
MetaVia has 6,588,101 shares outstanding.
What happened to MetaVia’s price movement after its last earnings report?
MetaVia reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.82. Following the earnings report the stock price went up 2.759%.
Which hedge fund is a major shareholder of MetaVia?
Currently, no hedge funds are holding shares in MTVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MetaVia
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
MTVA Stock 12 Month Forecast
Average Price Target
$14.00
▲(845.95% Upside)
Technical Analysis
Ownership Overview
2.96% Insiders
0.21% Mutual Funds
0.33% Other Institutional Investors
96.36% Public Companies and
Individual Investors